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IntroductIon
Molecular diagnosis of novel Mendelian disorders has traditionally 
relied upon genetic linkage studies in one or more pedigrees with 
multiple affected members. Wider assessment of the penetrance and 
phenotypic spectrum associated with the causal genetic defect(s) 
thus identified then permits targeted genetic testing in a clinical 
diagnostic setting. However despite the major advances achieved 
using this paradigm, it is estimated that fewer than half of the allelic 
variants responsible for Mendelian disease have been identified to 
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Genetic diagnosis of inherited metabolic disease is conventionally achieved through syndrome 
recognition and targeted gene sequencing, but many patients receive no specific diagnosis. 
Next-generation sequencing allied to capture of expressed sequences from genomic DNA now 
offers a powerful new diagnostic approach. Barriers to routine diagnostic use include cost, and 
the complexity of interpreting results arising from simultaneous identification of large numbers 
of variants. We applied exome-wide sequencing to an individual, 16-year-old daughter of 
consanguineous parents with a novel syndrome of short stature, severe insulin resistance, ptosis, 
and microcephaly. Pulldown of expressed sequences from genomic DNA followed by massively 
parallel sequencing was undertaken. Single nucleotide variants were called using SAMtools 
prior to filtering based on sequence quality and existence in control genomes and exomes. Of 
485 genetic variants predicted to alter protein sequence and absent from control data, 24 were 
homozygous in the patient. One mutation – the p.Arg732X mutation in the WRN gene – has 
previously been reported in Werner’s syndrome (WS). On re-evaluation of the patient several 
early features of WS were detected including loss of fat from the extremities and frontal hair 
thinning. Lymphoblastoid cells from the proband exhibited a defective decatenation checkpoint, 
consistent with loss of WRN activity. We have thus diagnosed WS some 15 years earlier than 
average, permitting aggressive prophylactic therapy and screening for WS complications, 
illustrating the potential of exome-wide sequencing to achieve early diagnosis and change 
management of rare autosomal recessive disease, even in individual patients of consanguineous 
parentage with apparently novel syndromes.
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date (Ng et al., 2010a). One explanation for this lies in the limita-
tions of positional cloning approaches, which may be thwarted by 
availability of only very small numbers of affected patients, some-
times exacerbated by locus heterogeneity in phenotypically similar 
disease. A further barrier arises in the clinical application of genetic 
knowledge, which may be confounded when patients are affected 
by an atypical syndrome, sometimes because of co-inheritance of 
more than one pathogenic mutation, or where early clinical signs 
of a syndrome are non-specific. As a result definitive diagnosis may 
be prevented or seriously delayed.
The rapidly developing technology of exome-wide sequencing 
has enormous potential to enhance the efficiency of molecular 
genetic diagnosis of inherited disease by circumventing barriers 
both to making novel associations between genes and disease, 
and to applying this research-derived knowledge to clinical diag-
nostics. This offers the opportunity for greatly improved pro-
spective management of known clinical complications. Recent 
improvements in efficiency of exome capture combined with 
next-  generation sequencing mean that sequencing of   increasing 
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numbers of exomes is being reported. Initial reports studied 
healthy individuals (Ng et al., 2008, 2009; Hedges et al., 2009) 
or those affected by Mendelian disorders with a known genetic 
basis (Ng et al., 2009) as proof of the concept that exome-wide 
sequencing can uncover pathogenic allelic variants. Subsequently 
exome sequencing (and to a lesser extent whole genome sequenc-
ing; Lupski et al., 2010; Rios et al., 2010) has been applied to 
identifying novel causes of Mendelian disease, using sequencing 
of unrelated individuals with highly similar phenotypes (Gilissen 
et al., 2010; Hoischen et al., 2010; Lalonde et al., 2010; Musunuru 
et al., 2010; Ng et al., 2010a,b), by studying multiple affected and 
unaffected individuals from one family (Bilgüvar et al., 2010; 
Krawitz et al., 2010) or by focusing on variants found in areas of 
interest from gene mapping (Bilgüvar et al., 2010; Sirmaci et al., 
2010; Walsh et al., 2010).
A small number of pathogenic mutations have been iden-
tified after sequencing the exome of just one patient with no 
other affected family members; in these cases the variants have 
occurred in genes previously implicated in Mendelian disease 
(Choi et al., 2009; Bonnefond et al., 2010; Rios et al., 2010). 
However, the large number of rare sequence variants harbored 
by every exome poses a major challenge to the routine diagnos-
tic use of the technology for individual patients. Nevertheless 
such evaluation of a single patient with no classically identifiable 
Mendelian syndrome is likely to be the most common application 
of exome-wide sequencing in clinical practice. This report now 
expands upon early experience by describing the diagnostic use 
of exome-wide sequencing in a patient with a novel clinical syn-
drome including severe insulin resistance, leading to molecular 
diagnosis of Werner’s syndrome some 10–20 years in advance 
of the usual time of diagnosis.
MaterIals and Methods
exoMe-wIde sequencIng
The proband and her parents gave full informed consent for the 
use of exome-wide sequencing, in line with procedures approved 
by the NHS Cambridgeshire three research ethics committee, and 
in accordance with the principles of Helsinki. Specifically, consent 
was given to seek genetic defects that were believed to explain the 
proband’s clinical disease, and to inform the proband and her par-
ents of these, but not to inform her of any incidentally detected 
genetic variation, whether or not possibly conferring risk of other, 
unrelated disease.
Proband DNA was screened for pathogenic copy number vari-
ants with data from Affymetrix SNP 6.0 ultra high density chip 
analyzed using Genotyping Console (TM) software (Affymetrix, 
Santa Clara, USA). For exome sequencing, 20 μg of DNA were 
sheared to 100–400 bp using a Covaris S2 following manufac-
turer’s protocols and using the following settings: Duty Cycle, 
20%; Intensity, 5.0; Cycles/burst, 200; Duration, 90; Mode, Freq 
Sweeping. The sheared sample was quantified on a Bioanalyzer 
(Agilent, Santa Clara, USA). Fifteen micrograms of sheared DNA 
were end-repaired, A-tailed, and Illumina sequencing adapters 
ligated to the resulting fragments using the Illumina Paired-End 
DNA Sample Prep kit and protocol with the slight modification 
that the gel size selection step was replaced with SPRI bead purifica-
tion (Beckman Coulter, Brea, USA). Five micrograms of the library 
were hybridized to a NimbleGen Sequence Capture 2.1 M Human 
Exome Array   programmed to capture the NCBI consensus coding 
sequence (Pruitt et al., 2009; Roche NimbleGen, Madison, USA) 
following the manufacturer’s protocols with the modification that 
no pre-hybridization PCR was performed. The captured sample 
was washed and eluted in 50 μl of PCR-Grade water following 
manufacturer’s protocols. The eluted sample was added to a mix 
containing 2 mM MgCl2, 0.2 mM dNTPs, 0.5 μM PE.1, 0.5 μM 
PE.2, and 3 units of Platinum® Pfx DNA Polymerase (Invitrogen, 
Carlsbad, USA), and aliquoted into three individual wells of a plate 
and amplified using the following conditions: 94°C for 5 min fol-
lowed by 20 cycles of 94°C for 15 s, 58°C for 30 s, 72°C for 30 s, 
and a final extension of 72°C for 5 min. PCR products were puri-
fied using SPRI beads prior to sequencing. Captured libraries were 
sequenced on the Illumina Genome Analyzer II platform (Illumina, 
Little Chesterford, UK) as 54-bp paired-end reads.
data analysIs
MAQ (Li et al., 2008) software package v0.6.5 was used to map 
sequence reads to the human genome reference sequence (NCBI 
build 36). Duplicate fragments were removed using MAQ (v0.6.5) 
rmdup command. Alignments were converted from native MAQ 
map to SAM format using SAMtools software (Li and Durbin, 
2009). Base qualities were recalibrated using The Genome Analysis 
Toolkit (GATK) early access v02Oct2009 (McKenna et al., 2010). 
Single nucleotide variants (SNVs) were called using SAMtools 
v0.1.7 (Li and Durbin, 2009). SNVs were filtered to include only 
those with a minimum SNP quality of 25, minimum genotype qual-
ity of 20, a minimum depth of 4× and maximum depth of 1200×. 
SNVs were reported in VCF (variant calling file)1 format v3.3.
Because of the rarity of the patient’s syndrome we assumed that 
the causative mutation would not be present in control individu-
als. Perl scripts were used to filter SNVs against the NCBI dbSNP 
database Build ID 1292, then against SNVs in 179 individuals 
included in the 1000 Genomes Project pilot 1 data release (April 
2009, 100328; Durbin et al., 2010)3 and exome-wide sequencing 
data from 236 control individuals exomes. Variants were annotated 
against Ensembl version 54 and were defined as coding if they 
were non-synonymous, resulted in loss or gain of a stop codon, or 
occurred within essential splice sites. Since we hypothesized that 
the patient would have inherited a common ancestral allele from 
her consanguineous parents, Perl scripts were written to exclude 
SNVs which were not flanked by similarly homozygous SNPs, 
with the likely practical effect of excluding variants falsely called 
as homozygous in areas of low sequence depth.
confIrMatory sanger sequencIng
Variants which remained after filtering were confirmed by Sanger 
sequencing in the proband and both parents. PCR primers were 
designed using Primer3, and PCR products were purified using 
Agencourt® CleanSEQ® reagents (Agencourt Bioscience, Beverly, 
MA, USA) and sequenced in both directions using the BigDye® 
1http://www.1000genomes.org/wiki/doku.php?id = 1000_genomes:analysis:vcf3.3
2ftp://ftp.ncbi.nih.gov/snp/organisms/human_9606/database/organism_data/b129/
3ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/pilot_data/release/2010_03/pilot1/
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  aminotransferase was elevated at 96 IU/l (NR 7–56), triglyceride 
was elevated at 4.2 mmol/l (NR < 2.2), and high density lipopro-
tein (HDL)-cholesterol was low at 0.5 mmol/l (NR > 0.9). Sex 
Terminator  v3.1  Cycle  Sequencing  Kit  (Applied  Biosystems, 
PerkinElmer,  Foster  City,  CA,  USA)  and  an  ABI  3730  DNA 
sequencer  (Applied  Biosystems).  Sequence  analysis  was  per-
formed using Sequencher software (Gene Codes, Ann Arbor, 
MI, USA).
cell culture
Epstein Barr virus-transformed lymphoblastoid cells (LBLs) were 
generated as described previously (Pressman and Rotter, 1991), 
and maintained in RPMI with 15% fetal calf serum, 2 mmol/l 
l-glutamine, 100 U/l penicillin, and 100 μg/ml streptomycin in 
5% ambient CO2.
western blottIng
Whole cell extracts were resolved on 6% SDS-polyacrylamide gels 
followed by semi-dry transfer onto a PVDF membrane. Primary 
antibodies used were anti-ATR (H-300) and anti-MCM2 (N-19), 
both from Santa Cruz.
decatenatIon checkpoInt assay
Exponentially growing LBLs were treated with the topoisomerase 
inhibitor ICRF-183 (150 μM) for 4 h in the presence of colcimed 
(0.2 μg/ml), pelleted, swollen in 75 mM KCl for 10 min, fixed in 
Carnoy’s solution (3:1 methanol:acetic acid) for 10 min prior to 
staining with DAPI. Cells were then immobilized on poly-l-lysine 
coated slides by cytocentrifugation. The mitotic index and lev-
els of pseudo-mitosis were determined using a Zeiss Axioplan 
microscope.
assessMent of cellular g2-M checkpoInt
For ATR-dependent G2-M arrest cells were untreated or irradiated 
with 5 J/m2 UV-C (UV) and immediately seeded into complete 
medium, incubated for 2 h, before being cytospun onto poly-l-lysine 
coated slides, and stained with DAPI and anti-  phosphoHistone H3 
as previously described (Alderton et al., 2006). Cells from a patient 
with a previously described homozygous hypomorphic ATR muta-
tion were used as positive controls (O’Driscoll et al., 2003). For the 
ataxia telangiectasia mutated (ATM)-dependent G2-M arrest cells 
were either untreated or irradiated with 2 Gy ionizing radiation 
(IR) and processed as above.
results
case hIstory
The proband was born at term to parents of Pakistani origin who 
were first cousins. Her birth weight was 2.94 kg (10th centile) and 
head circumference 32 cm (3rd centile). Bilateral ptosis was noted 
at birth. There was mild motor developmental delay with hyper-
tonia of the upper limbs, but development was otherwise normal. 
At 6 years old acanthosis nigricans was noted (Figure 1A), and at 
8 years old both height and weight were progressing along the 50th 
centile, while head circumference was well below the 3rd centile 
(Figure 1B). There was mild hirsutism and signs of early puberty 
(Tanner B2P1). Oral glucose tolerance testing showed impaired 
glucose tolerance. At 10 years old insulin resistant diabetes was 
diagnosed with a fasting blood glucose of 8.3 mmol/l [normal 
range (NR) 3.9–5.5], concomitant plasma insulin of >990 pmol/l 
(NR  0–60)  and  HbA1c  of  6.8%  (NR  4.0–6.5).  Serum  alanine 
FiguRE 1 | Early clinical features of Werner’s syndrome in a 16-year-old 
female patient from a consanguineous family. (A) Clinical images of 
proband at (I) 7 years old and (II, III) 16 years old, showing truncal obesity and 
acanthosis nigricans in the neck and flexures at both ages, and marked loss of 
distal subcutaneous tissue from the arms by 16 years. (B) Growth chart 
showing failure of pubertal growth spurt, typical of Werner’s syndrome. 
(C) Pedigree diagram (HOCM, hypertrophic obstructive cardiomyopathy; DM, 
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At this stage further genetic evaluation was undertaken on a 
research basis. The proband was the only affected child of first cous-
ins, and thus had a predicted coefficient of inbreeding of 0.0625. 
This means that 6.25% of her genome was likely to be identical by 
descent. Allied to the lack of obvious candidate genes to explain 
her novel syndrome, this meant that neither targeted sequencing 
of genes falling within homozygous regions, nor undertaking con-
ventional autozygosity mapping were likely to reveal the pathogenic 
mutation. For this reason exome-wide sequencing of genomic DNA 
from the proband was undertaken.
exoMe-wIde sequencIng
Overall 140,768,194 sequencing reads (281,536,388 paired end 
reads) were generated, of which 61.87% were uniquely mapped to 
the targeted exome with mean coverage depth of 155.35. The initial 
list of 22,344 variants was refined to a final 24 rare homozygous 
variants predicted to affect protein sequence, and lying in regions 
homozygous by descent (Figure 2).
  hormone binding globulin was low at 11.4 nmol/l (NR 25–110). 
As all these features are characteristic of insulin resistance with 
hepatic   steatosis, metformin, and insulin were introduced. At this 
stage no further pubertal progression was apparent, but marked 
acanthosis nigricans persisted.
Extensive biochemical and genetic testing was undertaken in an 
unsuccessful attempt to find a unifying genetic diagnosis. Normal 
investigations included a karyotype, blood mitochondrial DNA 
screen (for MELAS, MERRF, LHON, and NARP mutations and 
deletions), muscle mitochondrial DNA screen, respiratory chain 
analysis of frozen muscle homogenate, CSF and blood lactate, serial 
echocardiograms, transferrin immunoelectrophoresis, serum crea-
tine kinase, flash electroretinogram, flash visual evoked potentials, 
urine amino and organic acids, sialic acid and oligosaccharides, and 
TORCH screen. Muscle biopsy showed only sparse focal lipid accu-
mulation within muscle fibers. Computed tomography of the brain 
showed scattered foci of intracranial calcification in the right parietal 
region, in the right basal ganglia, and in the left lateral ventricle.
Abnormal liver function tests persisted, but near normoglycemia 
was restored, allowing cessation of insulin and maintenance treat-
ment with metformin. (Table 1) Menarche occurred at 11 years 
and 1 month, but there was no discernible pubertal growth spurt, 
with linear growth ceasing at 12 years and a final height between 
the 0.4th and 2nd centile, and weight between the 2nd and 9th 
centile (Figure 1B). On re-evaluation at 16 years old she remained 
hirsute and oligomenorrhoeic with marked acanthosis nigricans 
(Figure 1A), microcephaly, and bilateral ptosis. Echocardiographic 
appearances were consistently normal.
Two of the proband’s younger sisters died in early childhood 
from dilated cardiomyopathy, while her father had hypertrophic 
obstructive cardiomyopathy diagnosed on clinical grounds. One 
paternal uncle had cleft palate and motor developmental delay, 
while another paternal uncle and grandfather had type 2 diabetes 
mellitus (Figure 1C).
Table 1 | Biochemical profile of proband and parents (postprandial).
  Family member  Reference 
    range
  iV-1  iii-3  iii-4 
Age, years  16  –  –  –
Sex  F  M  F  –
WRN genotype  p.Arg732X/p.Arg732X  p.Arg732X/WT  p.Arg732X/WT  –
Body mass index, kg/m2  19.5 (−0.4 SD)  –  –  18–25 (adult)
Glucose, mg/dl  12.2  8.1  8.2  4.4–8.3
Insulin, pmol/l  938  1120  543  0–60#
Leptin, μg/l  20.9  29.7  58.5  * 
  (2.4–24.4)  (7.8–31.7)  (14.9–60.2)
Adiponectin, mg/l  1.0  1.5  2.6  * 
  (4.4–17.7)  (2.8–9.9)  (2.6–14.9)
HDL-cholesterol, mmol/l  0.88  0.80  0.91  >0.91
Triglyceride, mmol/l  5.65  3.90  1.70  <2.26#
SHBG, nmol/l  11.1  20.5  28.6  20–110
*For leptin and adiponectin sex and BMI-matched reference ranges are shown in brackets below each data point.
#Fasting reference range.
FiguRE 2 | Data analysis algorithm for whole exome sequencing data 
and location of pathogenic WRN mutation. Data analysis algorithm used 
for filtering all single nucleotide variants (SNVs) identified using exome-wide 
sequencing, with numbers of variants left at each filtering step.www.frontiersin.org  March 2011  | Volume 2  | Article 8  |  5
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atr IMMunoblottIng and g2-M checkpoInt functIon
Both the proband and her mother were also heterozygous for a 
late essential splice donor site mutation in the Ataxia telangiestasia 
and Rad3-related (ATR) gene (IVS43 + 2T > C). A homozygous 
hypomorphic mutation of ATR, which encodes a key DNA dam-
age-sensing kinase, has previously been reported to cause Seckel 
syndrome, which includes severe microcephaly and growth retar-
dation (O’Driscoll et al., 2003). ATR signaling responds to single-
stranded regions of DNA generated at stalled replication forks and 
ATM-dependent signaling is activated in response to DNA double 
strand breaks. Detection of DNA breaks leads to G2-M checkpoint 
arrest. Since the relative microcephaly of the proband was not 
adequately explained by Werner syndrome, ATR expression and 
function were assessed in LBLs from the proband. No difference 
in either the size or expression of the ATR protein was appar-
ent compared to a wild type control (Figure 4A). Furthermore, 
LBLs from the proband exhibited a proficient DNA double strand 
break-induced ATM-dependent G2-M arrest following ionizing 
radiation (Figure 4B).
ValIdatIon and parental genotypIng
Sanger sequencing confirmed 21 of the 24 to be homozygous in the 
proband. Of those, 17 were heterozygous in both parents, 2 were 
homozygous in one parent and heterozygous in the other, and 2 
were homozygous in both parents. Three SNVs called homozygous 
on exome-wide sequencing were found to be either heterozygous 
(2) or homozygous (1) for the reference allele by Sanger sequenc-
ing in the proband. Of the 21 confirmed homozygous SNVs, only 
the p.Arg732X (c.2982C > T) nonsense mutation in the WRN gene 
(GenBank NM_000553.4; NP_000544.2), described in at least three 
unrelated patients with Werner syndrome (MIM #277700), had 
previously been implicated in Mendelian disease. Both parents 
were heterozygous for the mutation. None of the other 20 genes 
harboring homozygous mutations had previously been associated 
with any aspect of the proband’s clinical presentation, and nor was 
any plausible mechanistic basis for any such association appar-
ent. Moreover, on re-evaluation of the patient in the light of this 
result, frontal hair thinning and loss of subcutaneous tissue from 
the extremities (Figure 1A) were noted, both consistent with evolv-
ing Werner Syndrome. Importantly, because the informed consent 
given by the proband and her family for exome-wide sequencing 
permitted disclosure to the proband or third parties only of vari-
ants believed by the investigators to account for her clinical disease, 
these other variants are not listed in this report.
The WRN gene encodes a RecQ-like 3′-5′ DNA helicase with 
additional 5′-3′ exonuclease activity, and in common with nearly 
all pathogenic WRN mutations, the p.Arg732X mutation truncates 
the protein before the critical helicase domain (Figure 3A). As the 
cellular consequences of this mutation have not previously been 
described, and in view of the atypical presentation, further cellular 
evidence for loss of function of the WRN helicase was sought.
decatenatIon checkpoInt assay
As a consequence of DNA replication, the DNA strands of sister 
chromatids become intimately entangled, or catenated. To prevent 
chromosomal mis-segregation or DNA breakage during the sub-
sequent anaphase it is essential that such catenations are resolved 
(Damelin and Bestor, 2007), a process that is thought to be critically 
dependent on the activity of topoisomerase II (Luo et al., 2009). 
Delay in decatenation, for example through chemical inhibition 
of Topo II using the bisdioxopiperazine family of catalytic inhibi-
tors, activates the decatenation checkpoint (DCC), and prevents 
entry into mitosis (Damelin and Bestor, 2007). The WRN DNA 
helicase has previously been implicated as an important compo-
nent of the DNA DCC mechanism (Franchitto et al., 2003), with 
WRN deficient cells failing to show cell cycle arrest in response to 
topoisomerase inhibition. We thus sought to assess integrity of 
the DCC in LBLs from the proband as an indirect index of loss of 
function of the WRN helicase. Treatment of LBLs from both a wild 
type control and the proband with the topoisomerase inhibitor 
ICRF-187 induced strong G2-arrest, as determined by a dramatic 
decrease in mitotic index (Figure 3B). However only cells from the 
proband exhibited a defective DCC, indicated by increased levels 
of pseudo-mitosis following this treatment (Figure 3B). These 
findings are strongly supportive of loss of the cellular function of 
the WRN protein, and are in keeping with a clinical diagnosis of 
Werner syndrome.
FiguRE 3 | identification of a loss-of-function mutation in the WRN 
helicase (A). Homozygous p.Arg732X mutation in the WRN gene found in the 
proband, leading to truncation of the RecQ helicase domain and loss of both 
RecQ C-terminal (RQC) and helicase RNAseD C-terminal (HRDC) domains 
which mediate interaction with DNA and proteins by the WRN protein. 
(B) Impairment of the DNA decatenation checkpoint in lymphoblastoid cells 
from the proband. The inset shows a representative pseudo-mitosis. WT, wild 
type; Unt, untreated; WRN (R368X), cells from a Werner’s syndrome patient 
homozygous for the p.Arg368X pathogenic variant.Frontiers in Endocrinology  | Genomic Endocrinology    March 2011  | Volume 2  | Article 8  |  6
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WRN mutations have been reported, so it is possible that the muta-
tion carried by both parents does account for their tendency to 
severe IR, however given the high background prevalence of IR 
and type 2 diabetes in South Asian populations, this may instead 
by caused by other mutations, acting either independently of or 
synergistically with the WRN mutation.
The early clinical features of Werner syndrome, such as failure of 
the pubertal growth spurt, are relatively non-specific, and because 
clinical diagnostic criteria rely on complications that usually arise 
only in the 3rd decade onward, the average age at diagnosis of 
Werner syndrome is in the late 30s. In this case a further confound-
ing factor was the co-existence of microcephaly and bilateral ptosis, 
neither of which have been reported in Werner syndrome. It is most 
likely that these features are attributable to co-inherited recessive 
disease, leading to superimposition of more than one genetic syn-
drome, a phenomenon that is likely to be common in families with 
high degrees of consanguinity.
Although inspection of the list of rare homozygous variants 
found in the proband did not reveal any previously described genetic 
defects associated with microcephaly and ptosis, both the proband 
and her mother were heterozygous for a late essential splice donor 
site mutation in the ATR gene (IVS43 + 2T > C). As loss of ATR 
function in humans has been reported to cause Seckel syndrome, 
which includes severe microcephaly (O’Driscoll et al., 2003), and as 
both WRN and ATR have been reported to function in series in some 
DNA damage checkpoints (Otterlei et al., 2006; Damelin and Bestor, 
2007), we speculated that co-inheritance of WRN loss of function 
may result in mild loss of ATR function being clinically expressed 
in the form of microcephaly. However the normal electrophoretic 
appearance of ATR protein in cells from the proband, and preserva-
tion of the G2-M DNA damage checkpoint argues against significant 
loss of ATR function, though a subtle effect cannot be ruled out.
Early diagnosis of Werner syndrome in this case is likely to have 
considerable clinical benefits. It will enable (1) Early and concerted 
use of established primary preventative therapies in the proband, such 
as statins for cardiovascular disease and skin care to reduce the risk 
of ulceration, (2) Prospective screening and intervention for major 
complications of Werner’s syndrome including cancers, atherosclero-
sis and cataracts, and (3) Consideration of more experimental thera-
pies aimed at slowing the disease process. An example of this is high 
dose vitamin C therapy, recently shown to retard the premature aging 
process in a rodent model of Werner syndrome (Massip et al., 2010). 
In addition, molecular confirmation of the diagnosis enables carrier 
testing for other members of the family to be offered, with antenatal 
diagnosis available for couples at risk of having affected children.
In this case, a very stringent filter was used to remove variants 
occurring in any of the 415 available control genomes and exomes, 
yielding a small list of candidate homozygous mutations, among 
which a highly likely pathogenic mutation was found. However 
caution must be exercised in the use of such filtering in the setting 
of autosomal recessive disease, where carriers may plausibly exist in 
the control population. In some cases a less stringent filter remov-
ing only variants found above a certain allele frequency in controls 
may be more useful. Where to set this filter will rely in large part on 
the rarity of the syndrome being studied, and where no plausible 
pathogenic mutations are revealed, a progressive relaxation of the 
filtering stringency may be tried.
dIscussIon
Genetic loss of function of the WRN helicase in humans produces 
Werner syndrome, a progeria syndrome in which features of pre-
mature aging including cataracts, scleroderma, atherosclerosis, and 
malignancies begin to be become clinically manifest in the 3rd 
decade of life. Insulin resistance and diabetes are also well recog-
nized features of the condition, and have been reported at a young 
age (Epstein et al., 1966). Although clinical diagnostic criteria for 
Werner’s syndrome have been suggested (Nakura et al., 1994; Goto, 
1997; The International Registry of Werner’s syndrome)4, these are 
only applicable to the later stages of the disease once frank progeria 
has become apparent.
We describe the case of a 16-year girl in whom no unifying 
diagnosis had been made despite intensive and expensive investiga-
tion in the 10 years since she first presented with clinical features of 
severe insulin resistance. Although she still does not fulfill clinical 
diagnostic criteria for Werner syndrome, the high penetrance of 
mutations in the WRN gene and the defective DCC seen in her LBLs, 
allied to the frontal hair thinning, loss of subcutaneous tissue from 
the extremities, and lack of pubertal growth spurt, has permitted a 
confident diagnosis of Werner syndrome to be made.
Although IR is a characteristic feature of Werner syndrome, 
both the proband’s parents were also markedly insulin resistant, 
as evidenced by hyperinsulinemia and suppressed adiponectin and 
SHBG (Table 1). Her father, who was also obese, had striking acan-
thosis nigricans, and both parents had dyslipidemia and hyperin-
sulinemia. No metabolic evaluation of people with   heterozygous 
4http://www.pathology.washington.edu/research/werner/registry/registry.html
FiguRE 4 | (A) ATR protein expression in EBV-transformed lymphoblastoid 
cells from the proband compared to a wildtype control (WT). MCM2 is shown 
as a loading control. (B) Preserved G2-M cell cycle checkpoint in response to 
either ultraviolet light (UV) or ionizing radiation (IR), assessed by the rate of 
mitosis compared to untreated cells (Unt). Cells from a patient with biallelic 
hypomorphic mutation of ATR (ATR-S) are shown as a positive control for ATR 
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